ATLAS ACS-TIMI 46 compared the safety and efficacy of rivaroxaban, an oral direct factor Xa inhibitor, to placebo in patients with acute coronary syndromes.
MAIN RESULTS:
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial

Lancet. 2009 Jul 4;374(9683):29-38
PRESENTATIONS
TIMI 46 Slides
Atlas ACS2-TIMI 51 Poster (Alkhalfan, AHA 2019)